Elusys Therapeutics, Inc.
about us Elusys & Biodefense product news&events careers
Elusys Overview Leadership
Executive Team Board of  Directors
Anthrax & Bioterrorism Contract Experience Useful Links
Anthim Anthrax Antibody Anthim Publication
Press Releases Presentations
Our Values Working at Elusys Open Positions Benefits Location

NEWS & EVENTS

PRESS RELEASES 2006

2011   2010   2009   2008   2007   2006   2005   2004

 

December 13, 2006


Elusys and US Army Extend Biodefense Collaboration

 

October 16, 2006

 

Elusys Announces fall 2006 conference schedule

 

September 28, 2006

Elusys Presents Positive Data on Anthrax Therapeutic at ICAAC

 

July 13, 2006

 

 

Elusys Therapeutics Completes $23 Million Series D Venture Financing

 

June 21, 2006

 

 

Elusys' Anthrax Therapeutic, Anthim™, Granted FDA Orphan Drug Designation

 

April 20, 2006

Elusys Enters into Infectious Disease License and Collaboration Agreement with Medimmune, Inc.

 

March 29, 2006

Elusys Therapeutics Successfully Completes Human Clinical Study of Anthrax Therapeutic, Anthim™

 

february 16, 2006

Elusys’ Anthrax Drug, Anthim™, Superior to Antibiotic as a Post-Exposure Monotherapy

 

february 13, 2006

Elusys to Present New Post Exposure Efficacy Data for Anthrax Therapeutic, Anthim™, at ASM Bio Defense Research Meeting

 

january 24, 2006

 

 

 

Elusys Therapeutics’ CEO to Present at Anti-Infectives Industry Summit

 

 

 

 

 

 

 

  • Copyright© 2012 Elusys Therapeutics, Inc. All Rights Reserved.
  • contact us
  • site map
  • careers